These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 1538418)

  • 1. Dose escalation of radioantibody in a mouse model with the use of recombinant human interleukin-1 and granulocyte-macrophage colony-stimulating factor intervention to reduce myelosuppression.
    Blumenthal RD; Sharkey RM; Goldenberg DM
    J Natl Cancer Inst; 1992 Mar; 84(6):399-407. PubMed ID: 1538418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokine intervention permits dose escalation of radioantibody. An analysis of myelostimulation by bolus versus continuous infusion of IL-1/GM-CSF.
    Blumenthal RD; Sharkey RM; Forman D; Wong G; Goldenberg DM
    Cancer; 1994 Feb; 73(3 Suppl):1083-92. PubMed ID: 8306251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved experimental cancer therapy by radioantibody dose intensification as a result of syngeneic bone marrow transplantation.
    Blumenthal RD; Sharkey RM; Forman D; Wong G; Hess J; Goldenberg DM
    Exp Hematol; 1995 Sep; 23(10):1088-97. PubMed ID: 7656929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelosuppressive changes from single or repeated doses of radioantibody therapy: effect of bone marrow transplantation, cytokines, and hematopoietic suppression.
    Blumenthal RD; Alisauskas R; Lew W; Sharkey RM; Goldenberg DM
    Exp Hematol; 1998 Aug; 26(9):859-68. PubMed ID: 9694507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of hematopoietic growth factors to control myelosuppression caused by radioimmunotherapy.
    Blumenthal RD; Sharkey RM; Quinn LM; Goldenberg DM
    Cancer Res; 1990 Feb; 50(3 Suppl):1003s-1007s. PubMed ID: 2404578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronotolerance of experimental radioimmunotherapy: clearance, toxicity, and maximal tolerated dose of 131I-anti-carcinoembryonic antigen (CEA) IgG as a function of time of day of dosing in a murine model.
    Blumenthal RD; Reising A; Lew W; Dunn R; Ying Z; Goldenberg DM
    Eur J Cancer; 1999 May; 35(5):815-24. PubMed ID: 10505044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining the optimal spacing between repeat radioantibody doses in experimental models: is there an accurate measurement for hematopoietic recovery?
    Blumenthal RD; Alisauskas R; Juweid M; Sharkey RM; Goldenberg DM
    Cancer; 1997 Dec; 80(12 Suppl):2624-35. PubMed ID: 9406717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of cytokine intervention for improved radio-antibody dose delivery.
    Blumenthal RD; Sharkey RM; Haywood L; Behr T; Goldenberg DM
    Int J Cancer; 1997 Jul; 72(1):166-73. PubMed ID: 9212239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM; Ratain MJ; Van Echo DA; Rosner G; Egorin MJ; Budman DR; Vogelzang NJ; Norton L; Schilsky RL
    J Natl Cancer Inst; 1993 Aug; 85(16):1319-26. PubMed ID: 8340944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S; Broxmeyer HE; Hittelman WN; Papadopoulos NE; Chawla SP; Fenoglio C; Cooper S; Buescher ES; Frenck RW; Holian A
    J Clin Oncol; 1992 Aug; 10(8):1266-77. PubMed ID: 1634916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo administration of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF, interleukin-1 (IL-1), and IL-4, alone and in combination, after allogeneic murine hematopoietic stem cell transplantation.
    Atkinson K; Matias C; Guiffre A; Seymour R; Cooley M; Biggs J; Munro V; Gillis S
    Blood; 1991 Mar; 77(6):1376-82. PubMed ID: 1705839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematologic effects of interleukin-1 beta, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor in tumor-bearing mice treated with fluorouracil.
    Moore MA; Stolfi RL; Martin DS
    J Natl Cancer Inst; 1990 Jun; 82(12):1031-7. PubMed ID: 1693405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of BCL-1 murine B-cell leukemia with recombinant cytokines. Comparative analysis of the anti-leukemic potential of interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and their combination.
    Chelstrom LM; Finnegan D; Uckun FM
    Leuk Lymphoma; 1992 May; 7(1-2):79-86. PubMed ID: 1282065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of in vivo administration of IL-3 and IL-6, alone and in combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host disease and survival after murine haematopoietic stem cell transplantation.
    Atkinson K; Vos B; Kang-Er Z; Guiffre A; Seymour R; Gillis S
    Cytokines Mol Ther; 1995 Mar; 1(1):47-55. PubMed ID: 9384663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective, randomized trial of sequential interleukin-3 and granulocyte- or granulocyte-macrophage colony-stimulating factor after standard-dose chemotherapy in cancer patients.
    Palmeri S; Leonardi V; Danova M; Porta C; Ferrari S; Fincato G; Citarrella P
    Haematologica; 1999 Nov; 84(11):1016-23. PubMed ID: 10553163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in the duration of myelotoxicity associated with radioimmunotherapy with infusions of the hemoregulatory peptide, HP5b in mice.
    Alisauskas RM; Goldenberg DM; Sharkey RM; Blumenthal RD
    Int J Cancer; 1997 Jan; 70(3):323-9. PubMed ID: 9033635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-oxidant vitamins reduce normal tissue toxicity induced by radio-immunotherapy.
    Blumenthal RD; Lew W; Reising A; Soyne D; Osorio L; Ying Z; Goldenberg DM
    Int J Cancer; 2000 Apr; 86(2):276-80. PubMed ID: 10738257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open phase I study to assess the biological effects of a continuous intravenous infusion of Interleukin-3 followed by Granulocyte Macrophage-Colony Stimulating Factor.
    Bretti S; Gilleece MH; Kamthan A; Fitzsimmons L; Hicks F; Rowlands M; Bishop P; Picardo AM; Dexter TM; Scarffe JH
    Eur J Cancer; 1996 Jun; 32A(7):1171-8. PubMed ID: 8758249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interdependence of the radioprotective effects of human recombinant interleukin 1 alpha, tumor necrosis factor alpha, granulocyte colony-stimulating factor, and murine recombinant granulocyte-macrophage colony-stimulating factor.
    Neta R; Oppenheim JJ; Douches SD
    J Immunol; 1988 Jan; 140(1):108-11. PubMed ID: 2447166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.